2,660.00
-35(-1.30%)
Currency In JPY
Sector
Healthcare
Industry
Biotechnology
Employees
29
First IPO Date
April 08, 2015
| Name | Title | Pay | Year Born |
| Mr. Keita Mori MBA | Co-Founder, President, Executive Officer, Chief Executive Officer & Representative Director | 0 | 1967 |
| Mr. Naoki Tsukahara | Senior Corporate Officer | 0 | N/A |
| Mr. Keizo Nakada | Corporate Officer & Head of Production | 0 | N/A |
| Mr. Dai Chida | Senior Scientific Advisor | 0 | N/A |
| Mr. Shinya Hirata | Corporate Officer & Head of Research and Development | 0 | N/A |
| Dr. Kazumi Sawaguchi Ph.D. | Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan | 0 | N/A |
| Mr. Yoshihiro Kakutani | Corporate Officer of Management Administration | 0 | N/A |
| Mr. Toru Kawanishi | Co-Founder & Executive Chairman | 0 | 1967 |
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.